Inventor
SAGERT JASON
US18 patents
⚠️ This page may combine multiple inventors who share the name “SAGERT JASON”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CRISPR THERAPEUTICS AG
6 patentsUS11459372B2Oct 4, 2022
Gene-edited natural killer cells
CRISPR THERAPEUTICS AG3 citations72
US11591381B2Feb 28, 2023
Gene-edited natural killer cells
CRISPR THERAPEUTICS AG2 citations69
US12304968B2May 20, 2025
T-cells expressing anti-LIV1 chimeric antigen receptor
CRISPR THERAPEUTICS AG0 citations62
US12146157B2Nov 19, 2024
Anti-PTK7 immune cell cancer therapy
CRISPR THERAPEUTICS AG0 citations62
US11926676B2Mar 12, 2024
Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such
CRISPR THERAPEUTICS AG1 citations62
US12344655B2Jul 1, 2025
Gene-edited natural killer cells
CRISPR THERAPEUTICS AG0 citations58
UNIV CALIFORNIA
4 patentsUS10077300B2Sep 18, 2018
Activatable binding polypeptides and methods of identification and use thereof
UNIV CALIFORNIA42 citations97
US9169321B2Oct 27, 2015
Activatable binding polypeptides and methods of identification and use thereof
UNIV CALIFORNIA62 citations97
US11028162B2Jun 8, 2021
Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moieties
UNIV CALIFORNIA6 citations83
US12209120B2Jan 28, 2025
Activatable anti-VEGF scFv
UNIV CALIFORNIA0 citations62
STAGLIANO NANCY E
3 patentsUS8563269B2Oct 22, 2013
Modified antibody compositions, methods of making and using thereof
STAGLIANO NANCY E119 citations97
US8513390B2Aug 20, 2013
Modified antibody compositions, methods of making and using thereof
STAGLIANO NANCY E111 citations97
US8399219B2Mar 19, 2013
Protease activatable interferon alpha proprotein
STAGLIANO NANCY E46 citations97